Unresolved
We still don’t know whether anyone at this organisation has actually used this technology — zero lived-experience observations exist.
Not yet answered
What are we missing?
HealthAratus Intelligence
Caristo
Caristo DiagnosticsCaristo Intelligence
What the accumulated evidence, deployment record and lived experience actually show.
Intelligence lenses
Four ways of interrogating the same reality. Each changes the question, not the subject.
Do published findings about Caristo match what happens in practice?
Public evidence
Caristo wins FDA authorization for cardiovascular risk predictor
MedTech Dive
Public evidence
Caristo Diagnostics Receives FDA De Novo Authorization for CaRi-Heart AI Platform
HIT Consultant
What we know · what we don’t
Everything here is open to being corrected by someone who has seen it first-hand.
What we still don’t know
Nobody has answered these yet. Your experience can help us understand what is happening.
Matters of record
Settled elsewhere. Context for reading the above, not something practice can confirm.
- 2 public external signal(s) across 2 source(s).Recorded by HealthAratus
Tool intelligence
What HealthAratus understands
HealthAratus currently understands Caristo through company records and external market activity.
- Category
- imaging_diagnostics
What HealthAratus is still learning
HealthAratus is beginning to understand Caristo. As evidence and experience accumulate, what remains unclear will be stated here.
Evidence & claims
What this is built on
The material the questions above were built from, with its attribution.
CaRi-Heart is an AI platform that analyzes standard cardiac CT scans to quantify coronary inflammation. It measures perivascular fat density to provide data on underlying biological processes.According to Caristo Diagnostics
What Caristo Diagnostics states
The vendor’s own claims. Testable where practice can actually test them.
Stated capability
The platform identifies perivascular inflammation from standard cardiac CT scans.
According to Caristo Diagnostics
Does this change your workflow?
Independent and public evidence
Found in public sources. Not a clinician’s experience, and never presented as one.
Recent change
Caristo wins FDA authorization for cardiovascular risk predictor
According to MedTech Dive
A matter of record — context, not something practice can confirm.
Recent change
Caristo Diagnostics Receives FDA De Novo Authorization for CaRi-Heart AI Platform
According to HIT Consultant
A matter of record — context, not something practice can confirm.
Company participation
Not yet verified
A record of the reality forming around this technology already exists. No representative of the company has verified participation yet.
Claim your company profileReference
The stable facts, for interpreting everything above.
Overview
What it does
Caristo Diagnostics has developed CaRi-Heart, an AI-powered cardiac imaging analysis platform that quantifies coronary inflammation from standard cardiac CT angiography (CCTA) scans. The technology measures the Fat Attenuation Index (FAI) around coronary arteries, detecting perivascular inflammation that precedes…
Vendor & external product information, not independently verified by HealthAratus
Where it's used
Deployed in mixed settings
Parent Company
Caristo Diagnosticsvendor
How the reality here has changed
Not enough recorded activity across time yet to describe how the reality here has moved. As accounts of Caristo accumulate, this becomes a record of how the reality moved rather than a snapshot of one moment.
Connected intelligence
Category intelligence